10-Q: Agilon Health Reports Q2 2024 Results: Revenue Up 39%, Membership Grows 38%

Agilon Health's second quarter 2024 results show a significant increase in revenue and membership, but also a net loss and a decrease in gross profit compared to the same period last year.

Summary

• Agilon Health's Q2 2024 revenue increased by 39% to $1.5 billion compared to Q2 2023, driven by a 38% increase in Medicare Advantage members to approximately 512,800.
• The company's gross profit decreased by 41% to $32 million, and medical margin decreased by 21% to $106 million compared to the same quarter last year.
• Agilon reported a net loss of $31 million for the quarter, compared to a $17 million loss in Q2 2023, and an adjusted EBITDA loss of $3 million compared to earnings of $12 million in the same period last year.
• For the first six months of 2024, total revenue increased by 45% to $3.1 billion, while the net loss was $37 million compared to a $1 million loss in the first half of 2023.
• The company's CMS ACO Models attributed beneficiaries increased by 51% to approximately 131,700 as of June 30, 2024.
• The company experienced a reduction of $55.9 million in medical services revenue and $54.3 million in medical services expense due to selected payor contract terminations retroactively effective January 1, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results with strong revenue and membership growth offset by significant declines in profitability and a net loss. The company also faces legal challenges and internal control weaknesses, which contribute to a negative sentiment.

Positives

• The company experienced significant growth in Medicare Advantage membership, increasing by 38% year-over-year.
• Total revenue increased by 39% in Q2 2024 and 45% in the first six months of 2024, indicating strong business expansion.
• The company's CMS ACO Models attributed beneficiaries increased by 51%, demonstrating growth in other care models.
• The company has expanded its operations into new geographies, including Lexington, Kentucky and Augusta, Georgia, along with additional partnerships in existing markets.

Negatives

• Gross profit decreased by 41% in Q2 2024 and 16% in the first six months of 2024, indicating a decline in profitability.
• Medical margin decreased by 21% in Q2 2024 and 9% in the first six months of 2024, suggesting increased medical costs.
• The company reported a net loss of $31 million in Q2 2024 and $37 million in the first six months of 2024, compared to losses of $17 million and $1 million respectively in the same periods of 2023.
• Adjusted EBITDA decreased to a loss of $3 million in Q2 2024 and $26 million for the first six months of 2024, compared to earnings of $12 million and $37 million respectively in the same periods of 2023.
• The company experienced a reduction of $55.9 million in medical services revenue and $54.3 million in medical services expense due to selected payor contract terminations.

Risks

• The company has a history of net losses and expects expenses to increase in the future.
• There is a risk of failure to identify and develop successful new geographies, physician partners, and payors.
• Medical expenses incurred on behalf of members may exceed revenues received.
• The company's ability to maintain and secure additional contracts with Medicare Advantage payors on favorable terms is uncertain.
• The company's ability to grow new physician partner relationships sufficient to recover startup costs is a risk.
• The company relies on a limited number of key payors, creating a concentration risk.
• The company is subject to the risk of inaccurate estimates of members' risk adjustment factors, medical services expense, and incurred but not reported claims.
• The company is involved in three putative class action lawsuits alleging securities fraud claims.
• The company has identified a material weakness in its internal control over financial reporting and is working to remediate it.

Future Outlook

The company expects to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to investments in expanding the business and additional general and administrative costs related to operating as a public company. The company believes that its existing cash and cash equivalents, investments in marketable securities, and available borrowing capacity will be sufficient to meet its working capital and capital expenditure needs over at least the next 12 months, though additional capital may be required in the future.

Management Comments

• The company's business model is differentiated by its focus on existing community-based physician groups.
• The company's goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model.
• The company believes that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model.

Industry Context

The company operates in the healthcare industry, specifically focusing on Medicare Advantage and value-based care. The growth in membership and revenue reflects the increasing adoption of Medicare Advantage plans and the shift towards value-based care models. The company's focus on empowering primary care physicians aligns with industry trends emphasizing the importance of primary care in managing healthcare costs and improving patient outcomes. The company's participation in CMS ACO Models also reflects the broader industry trend of accountable care organizations.

Comparison to Industry Standards

• Agilon's revenue growth of 39% in Q2 2024 is significant, but its profitability metrics, such as gross profit and medical margin, have declined, which may be a concern compared to industry benchmarks.
• The company's adjusted EBITDA loss of $3 million in Q2 2024 contrasts with some competitors in the value-based care space that are reporting positive EBITDA, indicating potential challenges in cost management.
• The 38% growth in Medicare Advantage membership is strong, but it is important to compare this to the growth rates of other companies in the same sector to assess its relative performance.
• The company's participation in CMS ACO Models is in line with industry trends, but the financial performance of these models needs to be evaluated against industry averages.
• The company's focus on long-term partnerships with existing physician groups is a differentiating factor, but its success will depend on its ability to manage costs and improve patient outcomes effectively.

Management Changes

Legal Proceedings

• The company is involved in three putative class action lawsuits alleging securities fraud claims related to statements made in the company's annual and quarterly reports and earnings releases.

Related Party Transactions

• The company's largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (CD&R), a private equity firm, and all funds affiliated with CD&R are considered related parties.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and declining profitability.
• Employees may be affected by the company's efforts to manage costs and improve financial performance.
• Customers (Medicare Advantage members) may be impacted by changes in the company's operations and service delivery.
• Physician partners may be affected by changes in compensation and risk-sharing arrangements.
• Payors may be impacted by the company's contract terminations and financial performance.

Next Steps

• The company will continue to focus on expanding its business and improving its financial performance.
• The company will work to remediate the material weakness in its internal control over financial reporting.
• The company will continue to monitor the impact of payor contract terminations on its financial results.

Key Dates

Keywords

Medicare Advantage, capitation, medical services, healthcare, physician partners, ACO REACH, risk-bearing, membership growth, financial results, EBITDA